Efficacy of Adalimumab Therapy in Patients with Crohn's Disease Who Were Unresponsive to or Intolerant of Infliximab: Six Years of Experience in a Single Gastroenterology Center

被引：1
|
作者：
Shafran, Ira [1 ]
Cangemi, David [1 ]
Burgunder, Patricia [1 ]
机构：
[1] Shafran Gastroenterol Ctr, Winter Pk, FL USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2010年 / 105卷
关键词：
D O I：
10.14309/00000434-201010001-01212
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1212
引用
收藏
页码：S444 / S444
页数：1
相关论文
共 50 条
  • [41] Efficacy and Safety of Certolizumab Pegol in patients with active Crohn's Disease who previously lost response or were intolerant to Infliximab: Open-Label induction results of the WELCOME Study
    Vermeire, S.
    Abreu, M.
    D'Haens, G.
    Colombel, J.
    Mitchev, K.
    Fedorak, R.
    Spehlmann, M.
    Lee, S.
    Sandborn, W.
    Rutgeerts, P.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S30 - S30
  • [42] Efficacy of infliximab therapy in pediatric patients with refractory Crohn's disease.
    Fleming, ZI
    Gremse, DA
    Crissinger, KD
    JOURNAL OF INVESTIGATIVE MEDICINE, 2004, 52 (01) : S269 - S269
  • [43] Frequency and Predictors of Loss of Response to Infliximab or Adalimumab in Crohn's Disease after One-Year Treatment Period - A Single Center Experience
    Molnar, Tamas
    Farkas, Klaudia
    Nyari, Tibor
    Szepes, Zoltan
    Nagy, Ferenc
    Wittmann, Tibor
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2012, 21 (03) : 265 - 269
  • [44] Efficacy and safety of certolizumab pegol in patients with active Crohn's disease who previously lost response or were intolerant to infliximab: Open-label induction preliminary results of the welcome study
    Vermeire, Severine
    Abreu, Maria T.
    D'Haens, Geert
    Colombel, Jean-Frederic
    Mitchev, Krassimir
    Fedorak, Richard
    Raedler, Andreas
    Sandborn, William J.
    Rutgeerts, Paul J.
    GASTROENTEROLOGY, 2008, 134 (04) : A67 - A68
  • [45] Adalimumab Effectiveness Up to Six Years in Adalimumab-naive Patients with Crohn's Disease: Results of the PYRAMID Registry
    Loftus, Edward V., Jr.
    Reinisch, Walter
    Panaccione, Remo
    Berg, Sofie
    Alperovich, Gabriela
    Bereswill, Mareike
    Kalabic, Jasmina
    Petersson, Joel
    Thakkar, Roopal
    Robinson, Anne M.
    D'Haens, Geert
    INFLAMMATORY BOWEL DISEASES, 2019, 25 (09) : 1522 - 1531
  • [46] In Patients With Crohn's Disease, Timing of Switching From Infliximab Maintenance Therapy to Adalimumab Affects Patients' Prognosis
    Takeuchi, Ken
    Yamada, Akihiro
    Suzuki, Yasuo
    GASTROENTEROLOGY, 2014, 146 (05) : S382 - S382
  • [47] Observational Study of Treatment Patterns in Patients Newly Initiated with Adalimumab or Infliximab Therapy for Crohn's Disease
    Plevy, Scott
    Lu, M.
    Yu, Andrew
    Sharma, Hari
    Chao, Jingdong
    Mulani, Parvez
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S479 - S479
  • [48] ADALIMUMAB IS EFFECTIVE IN THE TREATMENT OF ACTIVE LUMINAL CROHN'S DISEASE AND MUCOSAL HEALING: A SINGLE CENTER EXPERIENCE IN 170 PATIENTS
    Tambasco, R.
    Gionchetti, P.
    Brugnera, R.
    Straforini, G.
    Calabrese, C.
    Liguori, G.
    Campieri, M.
    Rizzello, F.
    DIGESTIVE AND LIVER DISEASE, 2010, 42 : S86 - S87
  • [49] A single centre experience of adalimumab treatment in patients with luminal and fistulizing Crohn's disease: do antibodies to infliximab affect clinical outcome?
    West, R. L.
    Kuipers, E. J.
    van der Toorn, P.
    Buster, E. H. C. J.
    Mensink, P. B. F.
    Wolbink, G. J.
    van der Woude, C. J.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2008, 20 (07) : A3 - A4
  • [50] High-Dose Infliximab Therapy in Crohn's Disease: Clinical Experience, Safety, and Efficacy
    Hendler, Steven A.
    Cohen, Benjamin L.
    Colombel, Jean-Frederic
    Sands, Bruce E.
    Mayer, Lloyd
    Agarwal, Shradha
    JOURNAL OF CROHNS & COLITIS, 2015, 9 (03): : 266 - 275
12345